Tag Archives: Alzheimer’s

High-profile Biogen ads hype early Alzheimer’s detection as hospitals reject Aduhelm prescriptions

How do you sell an Alzheimer’s treatment mired in controversy over its disputed benefits? Biogen is turning to “Jim and Jane” for help.  That’s the couple grappling with the memory-robbing disease that Biogen and Japanese partner Eisai have placed at the center of their new marketing campaign, “It’s Time We Know.” The campaign is designed… Read More »

Aduhelm and Alzheimer’s Disease: A Potential Medicare Budget-Buster Puts A Blazing Light on Health Care Costs and Innovation

The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue). In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s… Read More »

Biogen Alzheimer’s drug and the battle over dementia treatment of the future

Aduhelm by Biogen Source: Biogen The FDA’s approval of Biogen‘s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen. The director of the Alzheimer’s Therapeutic Research Institute at USC has spent the past three decades focused on treating the neurodegenerative disease, and in recent years helped shepherd this particular drug… Read More »